



Biotech Daily

Monday February 26, 2018

Daily news on ASX-listed biotechnology companies

- * ASX UP, BIOTECH EVEN: DIMERIX UP 11%; PRANA DOWN 7%
- * PERKINELMER BUYS RHS FOR \$25m
- * REVA FANTOM ENCORE CE MARK, 1st IMPLANT
- * ALLERGAN PAYS A TOTAL OF \$331m FOR ELASTAGEN
- * INVITROCUE \$100k NORTHERN IRELAND CANCER DRUG SCREEN GRANT
- * UNIVERSAL BIO REVENUE UP 34% TO \$25m, PROFIT TO \$765k LOSS
- * COMPUMEDICS H1 REVENUE DOWN 1% TO \$16m, PROFIT UP 184% TO \$641k
- * IDT H1 REVENUE UP 2% TO \$5m, PROFIT TO \$3m LOSS
- * MACH7 H1 REVENUE DOWN 19% TO \$3.9m, LOSS DOWN 14% TO \$3.4m
- * LBT H1 REVENUE UP 530% TO \$3.5m, LOSS UP 407% TO \$1m
- * MEDADVISOR H1 REVENUE UP 111% TO \$3.3m, LOSS UP 11% TO \$2m
- * OSPREY H1 REVENUE UP 179% TO \$2m, LOSS UP 22% TO \$18m
- * RESAPP PLEADS SCHULTZ TO ASX 58% QUERY
- * QUEENSLAND BAUXITE \$4m FOR ISRAEL MS MARIJUANA STUDY
- * ANTISENSE INJECTABLE ATL1103 FOR EUROPEAN ACROMEGALY PATIENTS
- * ITL LAUNCHES SAMPLOK ADAPTER CAPS
- * MALAYSIA APPROVES BIOXYNE MYMANA MILK, HONEY PRODUCT
- * CARESTREAM LAUNCHES MICRO-X DRX REVOLUTION NANO X-RAY SYSTEM
- * NUHEARA STARTS IQBUDS BOOST PRODUCTION
- * HARVEST ONE CONVERSION REDUCES MMJ TO 34.5%

MARKET REPORT

The Australian stock market was up 0.71 percent on Monday February 26, 2018 with the ASX200 up 42.4 points to 6,042.2 points. Eighteen of the Biotech Daily Top 40 stocks were up, 17 fell, four traded unchanged and one was untraded. All three Big Caps rose.

Dimerix was the best, up 1.5 cents or 11.1 percent to 15 cents with 1.2 million shares traded. Factor Therapeutics and Mesoblast climbed more than 10 percent; LBT was up 8.8 percent; Pharmaxis and Universal Biosensors were up more than seven percent; Compumedics rose 6.85 percent; Impedimed was up five percent; Immutep improved 4.55 percent; with Genetic Signatures, Oncosil and Pro Medicus up more than three percent.

Prana led the falls, down 0.4 cents or 6.9 percent to 5.4 cents with 369,281 shares traded. Optiscan fell 6.7 percent; Reva was down 5.6 percent; Avita fell 4.8 percent; Psivida and Uscom were down more than three percent; with Benitec and Volpara down more than two percent.

[RHS \(REPRODUCTIVE HEALTH SCIENCE\)](#)

RHS says the Waltham, Massachusetts Perkinelmer Inc will acquire it for \$25,177,735 through a scheme of arrangement.

RHS said that the 28 cents a share offer price was a 100 percent premium to closing price on February 23, 2018 and a 101 percent premium to the five-day volume-weighted average price to that date.

The company said that the acquisition would be through a scheme of arrangement pending shareholder and other approvals, with a scheme meeting expected to be held on May 22, 2018.

RHS has been attempting to commercialize its Embryocollect pre-implantation genetic screening test for in-vitro fertilization.

RHS was up 12.5 cents or 89.3 percent to 26.5 cents with 3.95 million shares traded.

[REVA MEDICAL](#)

Reva says it has Conformité Européene (CE) mark approval and the first implant of its Fantom Encore bio-resorbable coronary scaffold.

Reva said that the Fantom Encore stent was 2.5 millimetres in diameter and its struts measured 95 microns.

The company said that the Kiel Germany-based Universitätsklinikum (University Hospital) Schleswig-Holstein's Dr Matthias Lutz conducted the first implant.

Dr Lutz said the Fantom Encore had a "successful implantation procedure" and that the product was "easy to see with x-ray".

Reva said the Fantom Encore offered a thinner strut profile than the original Fantom, without sacrificing strength or x-ray visibility.

In 2017, the company said it had received CE mark approval for its original Fantom coronary scaffold (BD: April 4, 2017).

Today, the company said it was pursuing CE mark approval for the 3.0mm and 3.5mm diameter sizes and expected to launch the complete Fantom Encore product line later this year.

Reva chief executive officer Dr Reggie Groves said that approval of the Fantom Encore was "a significant milestone in bio-resorbable polymer and scaffold technology".

"Reva developed a novel polymer, Tyrocore, and then used it to create a bio-resorbable scaffold with the most advanced features available, x-ray visibility and a 95 micron profile," Dr Groves said.

Reva fell 2.5 cents or 5.6 percent to 42.5 cents.

[ELASTAGEN, BRANDON CAPITAL, MRCF GBS VENTURES](#)

Sydney skin and wound repair company Elastagen says Allergan will pay up to \$US260 million (\$A331 million) to acquire the company.

Earlier this month Elastagen said it would pay \$US95 million (\$A120.3 million) plus contingent and commercial payments (BD: Feb 7, 2018).

Elastagen director Dr Stephen Thompson told Biotech Daily that Allergan had filed documents with the US Securities and Exchange Commission disclosing the details of the acquisition, including a further \$US165 million in potential milestone payments.

Elastagen is a private company.

INVITROCUE

Invitrocue says that Invest Northern Ireland will provide a \$100,000 grant for its oncology patient-derived organoids or Onco-PDO for personalized drug-screening.

Invitrocue chief executive officer Dr Steven Fang told Biotech Daily the \$100,000 grant was the first of three Invest Northern Ireland grants for which the company was applying.

The company said that the grant would support efforts in commercializing its Onco-PDO personalized cancer testing and assist in finding relevant partnerships.

Invitrocue said the project uses patient's own cancer cells or tumors to build living models or organoids to be screened against cancer drugs to help guide treatments.

Dr Fang said the project was "an important first step in our commercial translation of our Onco-PDO technology in the UK and European market".

"Northern Ireland's oncology expertise is world-renowned so it seemed the natural place for this project," Dr Fang said.

Invest Northern Ireland international business executive director Steve Harper said that the Invitrocue technology had "the potential to significantly improve patient outcomes for those affected by cancer".

Invitrocue was up half a cent or five percent to 10.5 cents.

UNIVERSAL BIOSENSORS

Universal Biosensors says revenue for the 12 months to December 31, 2017 rose 33.8 percent to \$25,191,280, with last year's \$1,250,276 net profit after tax turned to a \$764,717 loss.

Universal Biosensors' preliminary final report said that the previous Federal Government Research and Development Tax Incentive contributed to the previous profit, with expenses generally in-line with the previous year.

The company said that LifeScan's Onetouch Verio blood glucose test strips service fees increased 12.0 percent to \$19,992,641 for the year, with Siemens' Xprecia Stride Coagulation Analyzer strip revenue up 595.7 percent from \$584,550 to \$4,066,929.

Mr Legleiter said that Johnson and Johnson could give notice at any time once Universal Biosensors passed the \$US45 million mark in aggregate quarterly service fees, which it did last year (BD: Nov 15, 2017).

Mr Legleiter told a teleconference that at the current revenue rate for the Lifescan's blood glucose test strips, the buy-out cost for Johnson and Johnson would be \$42.8 million, but the company had not given any indication that it would exercise its option to buy-out the test strip manufacturing business.

Mr Legleiter said the company had a new strategy for 2018 and said that priorities included further market penetration, higher productivity and reduced manufacturing costs, as well as looking for new business opportunities with "revenue increasing measures leveraging strategic assets" and faster decision-making.

"We have another assay in development for Siemens," Mr Legleiter said.

Mr Legleiter said that although the indication was confidential it would be in the field of coagulation analysis and was multi-purpose.

Universal Biosensors said that research and development expenses fell 14.6 percent to \$10,828,879 or 43.0 percent of total revenue.

The company said that net tangible asset per share fell 12.5 percent from eight cents for the previous year to seven cents at December 31, 2017 and last year's 1.0 cents diluted earnings per share fell to 0.00 cents per share, with cash and equivalents of \$26,259,918 at December 31, 2017 compared to \$20,402,322 at December 31, 2016.

Universal Biosensors was up two cents or 7.3 percent to 29.5 cents.

COMPUMEDICS

Compumedics says revenue for the six months to December 31, 2017, fell 0.6 percent to \$16,101,000 with net profit after tax up 183.6 percent to \$641,000.

Compumedics said that sales of its brain monitoring equipment were up in all sectors, and all geographical regions.

The company said that net tangible assets per share was up 3.3 percent to 9.5 cents at December 31, 2017, with diluted earnings per share up 300 percent to 0.4 cents.

Compumedics said that cash and cash equivalents at December 31, 2017 was \$2,948,000 compared to \$5,721,000 at December 31, 2016.

Compumedics was up 2.5 cents or 6.85 percent to 39 cents.

IDT AUSTRALIA

IDT says revenue for the six months to December 31, 2017 was up 2.0 percent to \$4,989,000 with last year's profit turned to a net loss after taxation of \$3,058,000.

Last year, IDT reported revenue for the six months to December 31, 2016 of \$4,892,000 with a net profit after taxation of \$11,729,000, which included the sale of its CMax clinical trials unit at the Royal Adelaide Hospital (BD: Feb 21, 2017).

The company said that revenue from its generic pharmaceuticals showed a "modest increase ... with replenishment orders filled and profit shares received for both of [its] currently marketed finished dose products, temozolomide and pindolol".

IDT said that diluted loss per share increased 527.3 percent from 1.1 cents in the previous year to 6.9 cents for the six months to December 31, 2017, with net tangible asset per security down 12.5 percent to 10.5 cents and cash and cash equivalents of \$8,822,000 at December 31, 2017, compared to \$9,443,000 at December 31, 2016.

IDT fell 0.3 cents or 3.8 percent to 7.6 cents with 2.6 million shares traded.

MACH7 TECHNOLOGIES

Mach7 says that revenue for the six months to December 31, 2017, was down 19.3 percent to \$3,861,206 with net loss after tax down 13.9 percent to \$3,395,481.

Mach7 said that revenue came primarily from development and commercialization of image data products for healthcare enterprises.

The company said its post-consolidation diluted loss per share fell 25 percent to three cents for the six months to December 31, 2017, with net tangible assets per share down 40 percent to three cents and it had cash and cash equivalents of \$4,474,406 at December 31, 2017, compared to \$5,511,315 at December 31, 2016.

Mach7 fell seven cents or 20 percent to 28 cents.

LBT INNOVATIONS

LBT says its revenue for the six months to December 31, 2017 was up 530.3 percent to \$3,473,000 with net loss after tax up 406.8 percent to \$1,039,000.

LBT said it had received \$2.9 million from joint venture company Clever Culture Systems AG for reimbursement of expenses and \$437,000 in income.

The company said that diluted loss per share was up 311.1 percent to 74 cents for the six months to December 31, 2017, with net tangible assets per share up 28.9 percent to 6.47 cents and it held cash and cash equivalents of \$4,233,000 at December 31, 2017 compared to \$5,276,000 at December 31, 2016.

LBT was up 1.5 cents or 8.8 percent to 18.5 cents.

MEDADVISOR

Medadvisor says that revenue for the six months to December 31, 2017, was up 110.5 percent to \$3,258,000 with net loss after tax up 10.8 percent to \$2,263,439.

Medadvisor said that pharmacy subscriptions for its prescription reminder service continued to increase.

The company said that diluted loss per share was down 23.1 percent at 0.20 cents for the six months to December 31, 2017, with net tangible assets per share up 65.4 percent to 0.8757 cents and cash and cash equivalents of \$12,291,739 at December 31, 2017, compared to \$5,927,087 at December 31, 2016.

Medadvisor was unchanged at 5.3 cents.

OSPREY MEDICAL

Osprey says that revenue for the 12 months to December 31, 2017, was up 178.7 percent to \$US1,630,615 (\$A2,076,092) with net loss after tax up 22.2 percent to \$US14,336,411 (\$A18,253,037).

Osprey said that sales were from its cardiac dye reduction systems to protect patients from dye-related kidney disease.

The company said that diluted loss per share decreased 16.6 percent to 10 US cents for the 12 months to December 31, 2017.

Osprey said that net tangible assets per Chess depository instruments (CDIs) rose 11.8 percent to 9.5 US cents at December 31, 2017 compared to 8.5 US cents at December 31, 2016, with cash and cash equivalents of \$US32,134,848 at December 31, 2017, compared to \$US21,853,439 at December 31, 2016.

Osprey was unchanged at 30.5 cents.

RESAPP HEALTH

Resapp has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 58.2 percent from 7.9 cents on February 9 to 12.5 cents on February 23, 2018 and noted a significant increase in trading volume.

Resapp fell half a cents or 3.85 percent to 12.5 cents with 10.7 million shares traded.

QUEENSLAND BAUXITE

Queensland Bauxite says that subsidiary Medical Cannabis will provide \$US3 million (\$A3.8 million) for Israeli research into the use of marijuana for multiple sclerosis.

Queensland Bauxite said that Medical Cannabis through its wholly-owned subsidiary Medical Cannabis Research Group it had signed a research funding agreement with the Haifa, Israel-based Technion Institute.

The company said the agreement was based on research by the Technion's Prof David Meiri, who it said had "identified the synergistic relationship between the cannabis plant and the human genome that will form the basis for this research".

Queensland Bauxite said that Prof Meiri's objective was to identify specific cannabis compounds that could be used in clinical trials as a potential treatment for multiple sclerosis and the Medical Cannabis Research Group would fund the research for three years in return for an exclusive licence for any product derived from the research.

Queensland Bauxite fell 0.2 cents or 3.6 percent to 5.4 cents with 16 million shares traded.

ANTISENSE THERAPEUTICS

Antisense says an unnamed manufacturing facility in the US will formulate ATL1103 as an injectable for the treatment of acromegaly patients in Europe.

Antisense said that ATL1103, or atesidorsen, would be available under an early access program in select countries of the European Union.

The company said it had sufficient supplies of atesidorsen to potentially treat about 15 acromegaly patients for one year.

Antisense said that the unnamed manufacturing facility would begin formulation in late May 2018 and, in parallel, the company was working with the Amsterdam, The Netherlands-based early access provider Mytomorrows on the preparation of the documentation required for the regulatory approvals for the program, hoped to begin by October 2018.

The company said that the average cost for second line acromegaly treatment in Europe was about \$80,000 per patient per year.

Antisense was up 0.2 cents or 4.65 percent to 4.5 cents.

ITL HEALTH GROUP

ITL says it has launched the Samplok Adapter Cap 2 and Samplok Adapter Cap 3 for blood culture sample collection.

ITL said that the adapter caps were designed for use in hospitals and clinics where patient blood was collected for testing to confirm or rule out presence of bacterial infection in the blood.

The company said that there were millions of bacterial screening tests performed across the globe each year.

ITL said that its bio-medical division planned to launch multiple products over the next 12 months to expand its blood culture testing ancillaries portfolio and increase its presence in the \$3 billion global blood sector.

ITL fell half a cent or 1.5 percent to 33 cents.

BIOXYNE

Bioxyne says it has Malaysian registration approval for its Mymana milk and honey product and is applying for a Chinese import licence.

Bioxyne said the first shipment of 10,000 cans of Mymana to Malaysia was expected by June 30, 2018

The company said that Mymana was a formulation of "New Zealand colostrum, honey and dairy milk formula, boosted with vitamins and minerals for sustained energy".

Bioxyne said that colostrum, the first milk from mammals following birth, and honey had "positive effects on the immune system".

The company said that colostrum had growth factors to assist healthy development and a range of biomolecules for general health and well-being, with "substantial published scientific research on colostrum, focused in the areas of immunity, gut health, weight management and sports performance".

Bioxyne said that "natural New Zealand honey has wide ranging health benefits ... [and contained] antioxidants, vitamins, minerals, amino acids and enzymes that add to the immune system and general health and wellbeing"

"New Zealand honey tastes good and is also a superior and healthier sweetener than other sweetening ingredients," Bioxyne said.

Bioxyne fell 0.6 cents or 6.2 percent to 9.1 cents with 22.6 million shares traded.

[MICRO-X](#)

Micro-X says that its Rochester New York-based distributor Carestream Health has launched its DRX Revolution Nano miniature x-ray system (BD: Oct 4, 2017).

Micro-X said that the brochure, webpages, promotional video and an explanatory paper on carbon nano-tube x-ray technology were available at Carestream's website.

The company said it had three initial products in development including a mobile medical x-ray imager for hospitals, a version for deployed military use and a mobile security back-scatter imager and was establishing manufacturing for these products in a facility in Tonsley, South Australia.

Micro-X was up four cents or 9.8 percent to 45 cents.

[NUHEARA](#)

Nuheara says that production of its Iqbuds Boost sound filtering system has begun and pre-ordering was open.

Nuheara said the Boost Ear ID hearing device had clinical validation and "due to strong global market interest from distributors, retailers and consumers" it had brought forward its pre-order opening to today, with shipping expected from April 24, 2018.

Nuheara chief executive officer Justin Miller said the market response to Boost "has been overwhelming".

"We have yet to commence any consumer marketing campaigns for Boost and we have already received nearly 1,000 consumer pre-registrations," Mr Miller said.

Nuheara was up 0.9 cents or 13.4 percent to 7.6 cents with 19.2 million shares traded.

[MMJ PHYTOTECH](#)

MMJ says Canadian subsidiary Harvest One intends to convert debentures into shares on or about March 28, 2018.

MMJ said that after the conversion it would hold 53,333,333 shares or 34.5 percent of Harvest One.

MMJ was up one cent or 2.2 percent to 46.5 cents.